This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Sep 2011

UK-based Pharma Firms Ink Deal for Cancer Drug Programme

Under the agreement, Ark will provide manufacturing and related services to support the development of PsiOxus’ ColoAd1 programme for the treatment of colorectal cancer.

London-based Ark Therapeutics Group has signed a manufacturing partnership agreement with Oxford-based PsiOxus Therapeutics, under which Ark will provide manufacturing and related services to support the development of PsiOxus’ ColoAd1 programme for the treatment of colorectal cancer.

 

According to the deal, Ark will work with PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II clinical studies, using its suspension based single use system (ATOSUS).

 

Martyn Williams, chief executive of Ark, said PsiOxus will benefit from Ark’s experience in the regulatory CMC aspects of developing a gene-based medicine.

 

PsiOxus’ chief executive John Beadle added: "Of critical impor

Related News